China’s approval of felzartamab adds a third CD38 inhibitor to the multiple myeloma market, offering patients another targeted treatment option.
Biogen's Monoclonal Antibody Felzartamab Enters China's Multiple Myeloma Market
China’s approval of felzartamab adds a third CD38 inhibitor to the multiple myeloma market, offering patients another targeted treatment option.